Botanical Ingredient

Silybin Safety Tips

Handling of Silybin should only be performed by personnel trained and familiar with handling potent active pharmaceutical ingredients. Moderate to severe irritant to the skin and eyes.

References

• 1. Synchronized and controlled release of multiple components in silymarin achieved by the osmotic release strategy.
  Xie Y, Lu Y, Qi J, Li X, Zhang X, Han J, Jin S, Yuan H, Wu W.Int J Pharm. 2012 Dec 16. doi:pii: S0378-5173(12)01061-7.  10.1016/j.ijpharm.2012.12.007. [Epub ahead of print]
• 2. Seventy-two-hour release formulation of the poorly soluble drug silybin based on porous silica nanoparticles: In vitro release kinetics and in vitro/in vivo correlations in beagle dogs.
  Cao X, Deng W, Fu M, Zhu Y, Liu H, Wang L, Zeng J, Wei Y, Xu X, Yu J.Eur J Pharm Sci. 2012 Nov 2;48(1-2):64-71. doi: 10.1016/j.ejps.2012.10.012. [Epub ahead of print]
• 3. Absolute Configuration of Isosilybin A by X-ray Crystallography of the Heavy Atom Analogue 7-(4-Bromobenzoyl)isosilybin A.
  Sy-Cordero AA, Day CS, Oberlies NH.J Nat Prod. 2012 Nov 1. [Epub ahead of print]
• 4. Absorption and metabolism of milk thistle flavanolignans in humans.
  Calani L, Brighenti F, Bruni R, Del Rio D.Phytomedicine. 2012 Dec 15;20(1):40-6. doi: 10.1016/j.phymed.2012.09.004. Epub 2012 Oct 13.
• 5. Silybin/Silymarin treatment in chronic hepatitis C.
  Barbero-Becerra VJ, Méndez-Sánchez N.Ann Hepatol. 2012 Sep-Oct;11(5):731-3. No abstract available.
• 6. In vivo evaluation of silybin nanosuspensions targeting liver.
  Wang Y, Wang L, Liu Z, Zhang D, Zhang Q.J Biomed Nanotechnol. 2012 Oct;8(5):760-9.
• 7. Silibinin (Milk Thistle) potentiates ethanol-dependent hepatocellular carcinoma progression in male mice.
  Brandon-Warner E, Eheim AL, Foureau DM, Walling TL, Schrum LW, McKillop IH.Cancer Lett. 2012 Dec 29;326(1):88-95. doi: 10.1016/j.canlet.2012.07.028. Epub 2012 Aug 1.
• 8. Improving bioavailability of silybin by inclusion into SBA-15 mesoporous silica materials.
  Fu T, Lu J, Guo L, Zhang L, Cai X, Zhu H.J Nanosci Nanotechnol. 2012 May;12(5):3997-4006.
• 9. Silibinin, dexamethasone, and doxycycline as potential therapeutic agents for treating vesicant-inflicted ocular injuries.
  Tewari-Singh N, Jain AK, Inturi S, Ammar DA, Agarwal C, Tyagi P, Kompella UB, Enzenauer RW, Petrash JM, Agarwal R.Toxicol Appl Pharmacol. 2012 Oct 1;264(1):23-31. doi: 10.1016/j.taap.2012.07.014. Epub 2012 Jul 24.
• 10. Hepatoprotective and anti-inflammatory effects of silibinin on experimental preeclampsia induced by L-NAME in rats.
  Souza CO, Peraçoli MT, Weel IC, Bannwart CF, Romão M, Nakaira-Takahagi E, Medeiros LT, Silva MG, Peraçoli JC.Life Sci. 2012 Sep 4;91(5-6):159-65. doi: 10.1016/j.lfs.2012.06.036. Epub 2012 Jul 7.
• 11. A sensitive LC-MS/MS assay for the simultaneous analysis of the major active components of silymarin in human plasma.
  Brinda BJ, Zhu HJ, Markowitz JS.J Chromatogr B Analyt Technol Biomed Life Sci. 2012 Aug 1;902:1-9. doi: 10.1016/j.jchromb.2012.06.003. Epub 2012 Jun 12.
• 12. High-dose silibinin rescue treatment for HCV-infected patients showing suboptimal virologic response to standard combination therapy.
  Biermer M, Schlosser B, Fülöp B, van Bömmel F, Brodzinski A, Heyne R, Keller K, Sarrazin C, Berg T.J Viral Hepat. 2012 Aug;19(8):547-53. doi: 10.1111/j.1365-2893.2011.01572.x. Epub 2011 Dec 29.
• 13. Hepatitis C therapy in non-genotype 1 patients: the near future.
  Wartelle-Bladou C, Le Folgoc G, Bourlière M, Lecomte L.J Viral Hepat. 2012 Aug;19(8):525-36. doi: 10.1111/j.1365-2893.2012.01634.x. Review.
• 14. Silibinin inhibits tumor growth in a murine orthotopic hepatocarcinoma model and activates the TRAIL apoptotic signaling pathway.
  Bousserouel S, Bour G, Kauntz H, Gossé F, Marescaux J, Raul F.Anticancer Res. 2012 Jul;32(7):2455-62.
• 15. CHOP down-regulates cFLIP(L)  expression by promoting ubiquitin/proteasome-mediated cFLIP(L)  degradation.
  Noh HJ, Lee SJ, Sung EG, Song IH, Kim JY, Woo CH, Kwon TK, Lee TJ.J Cell Biochem. 2012 Dec;113(12):3692-700. doi: 10.1002/jcb.24242.
• 16. Inhibitory effect of silibinin on EGFR signal-induced renal cell carcinoma progression via suppression of the EGFR/MMP-9 signaling pathway.
  Liang L, Li L, Zeng J, Gao Y, Chen YL, Wang ZQ, Wang XY, Chang LS, He D.Oncol Rep. 2012 Sep;28(3):999-1005. doi: 10.3892/or.2012.1874. Epub 2012 Jun 19.
• 17. Therapeutic efficacy of silibinin on human neuroblastoma cells: Akt and NF-κB expressions may play an important role in silibinin-induced response.
  Yousefi M, Ghaffari SH, Soltani BM, Nafissi S, Momeny M, Zekri A, Behmanesh M, Alimoghaddam K, Ghavamzadeh A.Neurochem Res. 2012 Sep;37(9):2053-63. doi: 10.1007/s11064-012-0827-9. Epub 2012 Jun 21.
• 18. Silibinin modulates lipid homeostasis and inhibits nuclear factor kappa B activation in experimental nonalcoholic steatohepatitis.
  Salamone F, Galvano F, Cappello F, Mangiameli A, Barbagallo I, Li Volti G.Transl Res. 2012 Jun;159(6):477-86. doi: 10.1016/j.trsl.2011.12.003. Epub 2012 Jan 2.
• 19. Tacrine-silibinin codrug shows neuro- and hepatoprotective effects in vitro and pro-cognitive and hepatoprotective effects in vivo.
  Chen X, Zenger K, Lupp A, Kling B, Heilmann J, Fleck C, Kraus B, Decker M.J Med Chem. 2012 Jun 14;55(11):5231-42. doi: 10.1021/jm300246n. Epub 2012 May 24.
• 20. Complementary and alternative medicines in prostate cancer: from bench to bedside?
  Klempner SJ, Bubley G.Oncologist. 2012;17(6):830-7. doi: 10.1634/theoncologist.2012-0094. Epub 2012 May 22. Review.

Details